Abstract
Alzheimer's disease (AD) is a neurological illness that causes a wide range of cognitive symptoms linked to amyloid plaque deposition, neurofibrillary tangles, oxidative stress, and neuron death in the whole brain. Curcumin has shown promising efficacy in preclinical studies for AD treatment. However, it failed to exhibit expected clinical outcomes in clinical studies. Besides, this molecule has low stability, solubility, and bioavailability properties. Hence, scientists have synthesized several curcumin analogues to improve their bioavailability and biological activity. The purpose of this narrative review is to discuss the development of curcumin analogue synthesis published in 2016-2021 and its efficacy that reveals its effect as an anti-Alzheimer's candidate through in vitro, cell-based and in vivo studies. Pubmed and Scopus database search engine with the keywords "curcumin" AND "analogues" OR "analogs" AND "Alzheimer's" were used to find the relevant studies. In our review, we include sixteen eligible journal articles to discuss. Fifteen curcumin analogues exhibited promise efficacy in preclinical studies and are suitable for development as anti-Alzheimer's candidates. Further study should explore to confirm the curcumin analogues toxicity, develop an appropriate dosage form, and initiate clinical trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.